Paxman launches neuropathy device to cut chemotherapy nerve damage
Paxman has launched the Paxman Neuropathy System, a cryocompression device designed to reduce the risk and severity of chemotherapy-induced peripheral neuropathy. The rollout begins in parts of Europe as new clinical data and a scientific review add momentum to efforts to prevent a side effect that can derail cancer treatment and daily life.
Why it matters: - Chemotherapy-induced peripheral neuropathy, or CIPN, can cause numbness, pain, tingling and loss of sensation in the hands and feet. - CIPN can reduce quality of life and force dose reductions, delays or early stopping of chemotherapy. - Paxman’s new system targets a major unmet need in cancer care because there is no established standard preventive therapy for CIPN.
What happened: - Paxman announced the launch of the Paxman Neuropathy System, a cryocompression device designed to help lower the risk and severity of CIPN. - The launch marks Paxman’s first major product expansion beyond scalp cooling for chemotherapy-related hair loss. - The company is rolling out the system in the UK, France, Germany, the Netherlands, Spain and Italy after recent regulatory approvals. - Pilot programs are already running in the UK, with more European centers expected to follow in the coming months.
The details: - Paxman says the new device extends its onco-support portfolio beyond scalp cooling into other treatment-related side effects. - The company has been a global leader in scalp cooling for more than 25 years, a position strengthened by its 2025 acquisition of Dignitana. - CIPN affects millions of cancer patients worldwide each year and can interfere with walking, writing, dressing and sleeping. - Symptoms can persist long after treatment ends. - The device launch coincides with clinical data from a prospective, multicenter phase I/II study published in JCO Oncology Advances. - The study evaluated the Paxman Neuropathy System in patients receiving taxane-based chemotherapy. - The study found the device was safe and well tolerated and was associated with low CIPN rates. - Among 146 evaluable patients, no participant developed severe neuropathy. - Patient-reported clinically significant sensory symptoms stayed low throughout follow-up. - The launch also aligns with a scientific review in Therapeutic Advances in Medical Oncology on the causes, effects and prevention strategies for CIPN. - The review identified cryotherapy and cryocompression as among the most promising emerging interventions. - The announcement included a statement from Richard Paxman OBE, CEO of Paxman, who said the launch opens a new chapter for the company and expands its mission beyond hair-loss support. - Paxman said the system reflects its commitment to giving patients more control over treatment-related side effects.
Between the lines: - Paxman is trying to turn its scalp-cooling expertise into a broader oncology side-effect platform. - The timing suggests the company wants to pair commercial rollout with clinical evidence to build credibility in a field with limited prevention options. - The combination of a published study, a literature review and early market access gives the launch more weight than a typical product announcement.
What's next: - Ongoing pilot programs in the UK are expected to expand to additional European centers. - Research continues through the randomized SWOG-S2205-ICE-COMPRESS study in the United States. - A separate clinical study at Dana-Farber Cancer Institute is also evaluating the Paxman Neuropathy System. - Further data will help determine how broadly the device can fit into cancer care and CIPN prevention.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
The Madrid Wire
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.